DDInter1008 DDInter1940
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) upregulates {v} (Gene) ALAS1
ALAS1 {u} (Gene) is regulated by {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) upregulates {v} (Gene) IDI1
IDI1 {u} (Gene) is downregulated by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Ketoconazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)
Ketoconazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Ketoconazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Ketoconazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Ketoconazole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Ketoconazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tolvaptan (Compound) and Tolvaptan (Compound) resembles Vismodegib (Compound)
Ketoconazole (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Ketoconazole (Compound) upregulates ALAS1 (Gene) and ALAS1 (Gene) is regulated by ORM1 (Gene) and ORM1 (Gene) is bound by Vismodegib (Compound)
Ketoconazole (Compound) upregulates IDI1 (Gene) and IDI1 (Gene) is downregulated by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)